The present study demonstrated that metformin, alendronate, and their combination attenuate the progression of osteoarthritis by inhibiting the expression of RANK and RANKL on osteoblasts and osteoclasts (after ex vivo culturing of bone marrow cells) and decreasing the serum concentration of leptin and resistin. The gene discussed is RETN; the disease is osteoarthritis.